VAX-31 31-valent pneumococcal conjugate vaccine Updated Nov 6
Watch for OPUS-2 and OPUS-3 topline data in H1 2027, which will complete the adult Phase 3 package. Positive results would clear the path for BLA submission in H1 2028. The key risk to monitor is whether the serotype 3 and 12F noninferiority nuance versus Capvaxive becomes a regulatory or commercial issue. The stock has already had its primary binary catalyst (OPUS-1), so subsequent readouts are expected to be supportive but less dramatic movers.
- OPUS-1 met every prespecified primary endpoint, matching or beating the two leading adult PCV vaccines (Prevnar 20 and Capvaxive) on immunogenicity in a 4,047-patient trial, which drove a ~36% single-day stock gain on October 5, 2026.
- VAX-31 covers 31 serotypes, the broadest pneumococcal vaccine candidate in development, versus 20 (Prevnar 20) and 21 (Capvaxive) in currently marketed adult vaccines, addressing a large unmet need as serotype replacement drives residual disease.
- The adult pneumococcal vaccine market is estimated at roughly $8 billion annually, with Pfizer's Prevnar franchise generating $6.49 billion in 2025 and Merck's Capvaxive at $759 million, giving VAX-31 a large addressable market if approved.
- VAX-31 missed the stricter noninferiority bar (LBCI >0.667) on serotypes 3 and 12F versus Capvaxive, though both met the historical LBCI >0.5 threshold; this could be a focus of FDA review or physician adoption concerns.
- BLA submission is not expected until the first half of 2028, meaning no FDA approval decision is likely before 2029, leaving the stock without a near-term regulatory catalyst and exposed to execution risk across multiple remaining trials.
- The company is pre-revenue and burning cash rapidly (Q3 2026 net loss of $297 million, R&D expense of $270 million), and while the $3.4B cash position is substantial, the burn rate is accelerating.